Are there instances where you would offer erdafitinib instead of avelumab for maintenance therapy for FGFR3 mutated metastatic bladder cancer after stable disease on cisplatin/gemcitabine?

The short answer is 'no'. There are no data for supporting FGFR inhibition in a maintenance first-line setting for those with stable or responding disease on platinum-based chemotherapy and FGFR2/3 activating alterations. There are contrasting data suggesting that the activity of PD1/L1 inhibitors m...